Orexo strengthens the Executive Management Group

Orexo strengthens the Executive Management Group

Orexo recruits Robin Wright, with extensive experience from international
corporate finance and business development in the pharmaceutical and life
science sector, as responsible for Business & Commercial Development. Robin
Wright will be part of Orexo's Executive Management Group.

Robin Wright joins from BioScience Managers Limited, a specialist healthcare
fund manager and corporate finance boutique, where he held the position as Head
of Corporate Advisory Services. Robin has extensive experience in providing
financial and strategic advice and idea generation for life science companies.
Göran Smedegård, previously responsible for Business & Commercial Development,
leaves his position at Orexo but will continue to work as a consultant for the
company.

Orexo has also made some additional changes to the Executive Management Group.
Göran Tornling, Head of R&D, leaves Orexo and his responsibilities are divided
into two areas, pre-clinical research and development and clinical and 
pharmaceutical development. Charlotte Edenius will be responsible for
pre-clinical research and development and joins the executive management group.
Thomas Lundqvist, member of the Executive Management, will be responsible for
clinical and pharmaceutical development. 

“We are delighted over the recruitment of Robin Wright. He has demonstrated
success in over 130 transactions in over 40 countries. Robin is indeed a skilled
principal negotiator with excellent marketing and execution skills. Robin has a
perfect profile for us in our continued work to develop Orexo and find future
partners. The strengthening of the Executive Management Group is another step in
becoming a profitable pharma company.  I would also like to thank Göran Tornling
for his excellent contributions to Orexo and wish him all the best in his future
endeavours”, says Torbjörn Bjerke, President and CEO, Orexo AB.

For more information, please contact: 
Torbjörn Bjerke, President and CEO, Orexo AB
Tel: +46 (0)708-66 19 90
E-mail: torbjorn.bjerke@orexo.com
Claes Wenthzel, Executive Vice President & CFO, Orexo AB 
Tel: +46 (0)18-780 88 44 
E-mail: claes.wenthzel@orexo.com



TO THE EDITORS

About Orexo

Orexo is a pharmaceutical company, focusing on development of new, patented
drugs by combining well-documented substances with innovative technologies, and
the development of new treatments for respiratory and inflammatory diseases.

Orexo has a broad and competitive late-stage product portfolio, including two
marketed products, five products in clinical phase and two undergoing
registration. 

To date, Orexo have out-licensed the market rights for Rapinyl for the US, the
EU and Japan markets, the world-wide market rights for Sublinox (OX22) and
OX-NLA, and a out-license and research collaboration with Boehringer Ingelheim
regarding the development of a new class of drugs to treat pain and
inflammation. Also, Orexo has established a Nordic sales force by entering into
a joint venture with ProStrakan.

Orexo has head office in Uppsala and is listed on the OMX Nordic Exchange
Stockholm, Small Cap (ticker: ORX).  

www.orexo.com